Search Results - "Zobova, S. N."

Complement activation lectin pathway (mannose-binding lectin and ficolin) genes polymorphism as the risk factor of CagA positive chronic Helicobacter pylori infection in adolescents by Sergey Yu. Tereshchenko, Marina V. Smolnikova, S. N. Zobova

“…Currently, features of the host immune response against Helicobacter pylori (Hp) both regarding establishment of chronic carriage after primary infection as…”
Get full text

Association of the carriage of BRD2 rs206787 and rs516535 and GJD2 rs3743123 polymorphisms with juvenile myoclonic epilepsy in Caucasian patients of Siberia by Shilkina, O. S., Shnayder, N. A., Zobova, S. N., Dmitrenko, D. V., Moskaleva, P. V.

“…In recent years, the genetics of juvenile myoclonic epilepsy (JME) has been actively studied; the association of JME with the carriage of polymorphic allelic…”
Get full text

Genetic risk factors for behavioral adverse reactions in epileptic patients taking levetiracetam by Usoltseva, A. A., Dmitrenko, D. V., Zobova, S. N., Bochanova, E. N., Shnayder, N. A.

“…Levetiracetam (LEV) is an effective antiepileptic drug. Nevertheless, when the drug is used, its behavioral adverse drug reactions (ADRs), such as…”
Get full text

Mechanisms of valproate-induced teratogenesis by Dmitrenko, D. V., Shnaider, N. A., Strotskaya, I. G., Kichkaylo, A. S., Zobova, S. N.

“…The risks associated with in utero antiepileptic drug (AED) exposure are of great importance for both epileptic women and their offspring. This review…”
Get full text

The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches by Vlasov, P. N., Orekhova, N. V., Antonyuk, M. V., Filatova, N. V., Schnaider, N. A., Dmitrenko, D. V., Zobova, S. N., Poverennova, I. E., Yakunina, A. V., Kalinin, V. A., Zyryanov, S. K., Tishchenkova, I. F.

“…Objective: to analyze the efficacy and tolerability of sustained-release sodium valproate (SV) in adult patients with focal or generalized epilepsy in real…”
Get full text

Changes in mitochondrial NAD(P)H and glutamate-induced delayed calcium deregulation in cultured rat cerebellar granule neurons by Surin, A. M., Zobova, S. N., Tukhbatova, G. R., Senilova, Y. E., Pinelis, V. G., Khodorov, B. I.

“…Changes in cytosolic [Ca 2+ ] i , mitochondrial potential (ΔVm), and mitochondrial NAD(P)H autofluorescence were compared in experiments on cultured cerebellar…”
Get full text

Modification of membrane-toxic effect of Nd-YAG laser by preliminary induction of cytochrome P-450 in bone marrow cells by Stavitskaya, E Y, Egorova, A B, Salmin, V V, Zobova, S N, Provorov, A S

“…The cytotoxic effects of Nd-YAG laser with a wavelength of 533 nm were studied in mouse bone marrow cells in vitro. Laser exposure caused blebbing of bone…”
Get full text

Association of carriers of single nucleotide polymorphisms rs206787 and rs516535 in gene BRD2 and rs3743123 in gene GJD2 with juvenile myoclonic epilepsy of Caucasian patients in the Siberia by O. S. Shilkina, N. A. Shnayder, S. N. Zobova, D. V. Dmitrenko, P. V. Moskaleva

“…This article outlines recent findings on genetics of juvenile myoclonic epilepsy (JME), where JME occurrence is associated with polymorphic allelic variants in…”
Get full text

GENETIC RISK FACTORS FOR THE DEVELOPMENT OF BEHAVIORAL ADVERSE DRUG REACTIONS IN PATIENTS WITH EPILEPSY TAKING LEVETIRACETAM by A. A. Usoltseva, D. V. Dmitrenko, S. N. Zobova, E. N. Bochanova, N. A. Shnayder

“…Levetiracetam (LEV) is a highly effective antiepileptic drug (AED). However, unwanted behavioral adverse drug reactions (ADR), such as aggression,…”
Get full text

The effect of OPRM1, ABCB1, IL1B, PTGS2, LOC 541472 gene polymorphism on the variability of chronic pain syndrome in patients with pancreatic cancer by O. P. Bobrova, N. A. Schnider, S. K. Zyryanov, D V. Dmitrenko, S. N. Zobova, R. A. Zukov

“…Background. One of the obligate clinical manifestations of pancreatic cancer is chronic pain syndrome, which is realized in 80 % of patients with a progressive…”
Get full text